Chorus One, with $2.8B staked and $300M rewards paid, partners with top firms to deliver secure, compliant staking for upcoming crypto ETFs in 2025.Chorus One, with $2.8B staked and $300M rewards paid, partners with top firms to deliver secure, compliant staking for upcoming crypto ETFs in 2025.

Chorus One Sets Stage for Institutional-Grade Crypto ETF Staking Services

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
chorus-one
  • Chorus One has inked several strategic partnerships since 2018 to enhance regulatory compliance ahead of crypto staking ETF approvals in 2025 and beyond.
  • Chorus One provides institutional-grade staking, which is secure by design and not assumption, to over 40 PoS chains.
  • After the approval of REX – Osprey SOL + Staking ETF, investors anticipate the U.S. SEC to approve several other applications before the end of this year.
chorus

Chorus One, an institutional-grade staking platform, has signaled its readiness to provide top-notch services to fund managers seeking to offer staking in their spot crypto exchange-traded funds (ETFs). Having grown to a total of $2.8 billion in net assets staked, with over $300 million paid in rewards since 2018, Chorus One believes it is well prepared to provide staking services to crypto ETF issuers.

The United States Securities and Exchange Commission (SEC) is expected to approve several crypto ETT staking before the end of this year. Additionally, the U.S. SEC is keen to help investors earn more crypto staking rewards in a regulated environment, to fulfill the executive orders of President Donald Trump. Several major issuers – including BlackRock, Franklin Templeton, Fidelity, Bitwise, and 21Shares – have filed proposals requesting the SEC to allow staking in their crypto ETFs.

How Has Chorus One Prepared for the Upcoming Crypto ETFs Staking?

Tailored Institutional-grade Staking Products

Chorus One has developed innovative products in the past few years to optimize reliable institutional-grade staking. For instance, the Chorus One’s ETH Staking Vaults, a sophisticated non-custodial platform, offers investors an opportunity to earn more Ethereum rewards through EigenLayer and StakeWise.

Security Optimization by Design 

The recent attack on SwissBorg, which led to the loss of $41 million worth of SOL, has raised the need for enhanced staking protocol security. Furthermore, it was reported that the SwissBorg attack was facilitated by a compromise on APIs for staking provider Kiln.

In order to ensure maximum protection of investors’ funds, Chorus One uses a well-tested SDK as a library instead of an ordinary API interface. Most importantly, Chorus One has achieved ISO 27001:2022 certification, which is a well-known international standard for information security management. 

Strategic Partnerships to Enhance Regulatory Compliance

In a bid to enhance transparency, legal compliance, while optimizing investors’ rewards, Chorus One has inked strategic partnerships in the recent past. For example, Chorus One recently partnered with MEV Zone, a permissionless protocol designed to enhance transparency and standardized MEV (Maximal Extractable Value) on the Avalanche (AVAX) blockchain.

Chorus One has also partnered with institutional custody and prime brokers, including Cactus Custody, Utila and Ledger. Other notable strategic partnerships with Chorus One, which crypto ETF issuers need to adopt staking and restaking, include with FalconX and Hex Trust.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09